Thalidomide as a Potential Treatment for Scleromyxedema | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Sign In
The Cutting Edge
March 2004

Thalidomide as a Potential Treatment for Scleromyxedema

Author Affiliations


Arch Dermatol. 2004;140(3):277-280. doi:10.1001/archderm.140.3.277

Report of a case

A 39-year-old African American woman was referred in April 1995 with a 1-year history of skin thickening. The process began on her hands and progressed to involve her arms, face, neck, shoulders, chest, and proximal extremities. Her only systemic complaints were limited mobility of her joints, particularly her hands and wrists. Physical examination findings revealed leonine facies. The skin of the neck, shoulders, and chest exhibited 1- to 2-mm coalescent linear papules. The skin of the hands, forearms, upper arms, and trunk was sclerotic. Skin biopsy results showed marked dermal thickening, displacement of collagen bundles by mucin, and numerous spindled fibroblasts, consistent with scleromyxedema. The results of laboratory tests, including a complete blood cell count, chemistry tests, liver function tests, an antinuclear antibody panel, an extractable nuclear antigen panel, and thyroid function tests, were normal. Immunoglobulins were obtained, and the following levels were revealed: IgM, 92 mg/dL (reference range, 25-210 mg/dL); IgA, 152 mg/dL (reference range, 40-390 mg/dL); and IgG, 1490 mg/dL (reference range, 525-1650 mg/dL), with a λ light chain monoclonal gammopathy. Hematologic evaluations, including serum and urine protein electrophoresis, immunoelectrophoresis, a bone marrow examination, and radiography of the head and chest, produced no evidence of multiple myeloma.

Because of significant restriction of joint mobility, the patient underwent treatment with cytotoxic agents. She was initially treated with melphalan, 16 mg/d orally (PO), plus prednisone, 100 mg/d PO, for 4 days at a time in 1-month intervals for 4 cycles from June 1995 to September 1995, with little response. She was then treated with cyclophosphamide, 75 mg/d PO, plus prednisone, 100 mg/d PO, for 21 days at 1-month intervals for 6 cycles from October 1995 to March 1996, with minimal improvement. The patient was then administered prednisone, 40 mg every other day, from April 1996 to June 1996, again with no improvement. A trial of cladribine, 0.1 mg/kg, was instituted for 5 days at 1-month intervals for 5 cycles from September 1995 to January 1997, and was unsuccessful. The patient then received supportive therapy, including topical corticosteroids and emollients, and underwent physical therapy.

In February 1998, the patient developed status epilepticus, fever, and hypotension, requiring admission to the intensive care unit and mechanical ventilation. The findings of an examination for a cause of the patient's illness, including computed tomography, magnetic resonance imaging, and magnetic resonance angiography of the head, and of a complete infectious disease workup were negative. Because an organic brain syndrome was previously reported in association with scleromyxedema and there was no obvious other cause, this episode was attributed to scleromyxedema. The patient returned to her baseline level of function and was administered phenytoin (Dilantin), topical corticosteroids, and emollients. She declined further chemotherapy because of the lack of efficacy and intolerable adverse effects.

The patient's disease progressed to her lower extremities. She had difficulty walking and could no longer perform activities of daily living. She developed significant alopecia. The patient was regularly assessed for progression to multiple myeloma. Despite the persistence of the monoclonal gammopathy, she never developed marrow plasmacytosis, lytic bone lesions, or other signs of multiple myeloma. Even with obvious disease progression, further treatment with cytotoxic agents was abandoned because of lack of response and risk of a secondary malignancy.

Therapeutic challenge

Because of increasing disability, the patient required further therapy, but alkylating agents had proved ineffective and have unacceptable long-term adverse effects.


The patient began treatment with thalidomide, 100 mg/d PO, in March 2001. Before beginning thalidomide treatment, the patient was registered with the System for Thalidomide Education and Prescribing Safety (STEPS). In accordance with the STEPS guidelines, the patient was advised to use a barrier form of contraception even though she had a bilateral tubal ligation. The results of baseline pregnancy tests were negative. The results of baseline bilateral electromyography of the lower extremities were normal. She continued undergoing physical therapy and receiving emollients, but was not receiving any other treatment.

The patient tolerated thalidomide well. She experienced mild drowsiness that was minimized with evening dosing, but denied other adverse effects, including paresthesias. The patient returned to the clinic monthly for urine pregnancy tests and refills of thalidomide in accordance with STEPS. She quickly showed signs of improvement. Before starting thalidomide therapy, her IgG level (reference range, 525-1650 mg/dL) was elevated (2338 mg/dL), and 1 month after starting thalidomide therapy, her IgG level decreased to 1952 mg/dL. Within 6 months of starting thalidomide therapy, the patient began to notice decreased thickness of her skin and increased mobility. She became increasingly independent in her daily activities. After 1 year of treatment, the patient began to notice regrowth of her hair (Figure 1 and Figure 2). She has had no difficulty with paresthesias, and electromyography repeated every 6 months has not shown evidence of neuropathy. She has been receiving thalidomide for 1 to 2 years and continues to note improvement in her skin and in the mobility of her joints. Examination of a repeat biopsy specimen after 1 year of treatment with thalidomide showed a significant decrease in mucin (Figure 3 and Figure 4). Her IgG level has steadily increased to 2293 mg/dL, despite continued cutaneous improvement.

Figure 1. 
Before thalidomide therapy. A, Thickened skin, producing loss of facial expression and dermal appendages. B, Shiny flesh-colored papules coalesced into indurated plaques.

Before thalidomide therapy. A, Thickened skin, producing loss of facial expression and dermal appendages. B, Shiny flesh-colored papules coalesced into indurated plaques.

Figure 2. 
After 6 months of thalidomide therapy. A, Facial skin is softened, with return of facial expression. B, Resolution of indurated plaques, with regrowth of eyelashes.

After 6 months of thalidomide therapy. A, Facial skin is softened, with return of facial expression. B, Resolution of indurated plaques, with regrowth of eyelashes.

Figure 3. 
Before thalidomide therapy. The Alcian blue stain emphasizes mucin deposits (original magnification ×100).

Before thalidomide therapy. The Alcian blue stain emphasizes mucin deposits (original magnification ×100).

Figure 4. 
After 6 months of thalidomide therapy. The Alcian blue stain shows decreased dermal mucin deposition (original magnification ×100).

After 6 months of thalidomide therapy. The Alcian blue stain shows decreased dermal mucin deposition (original magnification ×100).


Scleromyxedema is a disorder of unknown cause, with fewer than 150 reported cases in the literature. It was first described by Dubreuilh in 19061 and Reitmann in 1908.2 In 1953, Montgomery and Underwood3 classified papular mucinosis into 4 clinical forms: a generalized lichenoid form, a discrete papular form, a discrete lichenoid plaque form, and a urticarial plaque form. In 1954, Gottron4 coined the term scleromyxedema to describe a unique variant of papular mucinosis corresponding to the generalized lichenoid form.

Scleromyxedema is a disorder of adults, usually affecting those between the ages of 30 and 50 years. It affects both sexes equally. Characteristic physical examination findings include 2- to 4-mm linear dome-shaped flesh-colored papules that coalesce into plaques. The lesions are symmetric and most commonly affect the dorsum of the hands and fingers; extensor surfaces of the arms, forearms, legs, and thighs; and axillary folds. On the face, the infiltrating lesions cause characteristic leonine facies. The widespread infiltration of the skin in patients with scleromyxedema can produce significant disability, as in our patient.

Systemic manifestations of scleromyxedema have been reported.5 The most common extracutaneous manifestation is plasma cell dyscrasia (usually IgG with a λ light chain).6 Other systemic manifestations include those that are neurologic, gastrointestinal, rheumatologic, pulmonary, and cardiovascular. Although an attempt has been made to correlate areas of internal mucin deposition and clinical symptoms, autopsies have not demonstrated mucin deposition in affected organs.7-9

The pathogenesis of scleromyxedema remains uncertain. Serum from patients with scleromyxedema has been shown to stimulate the proliferation of fibroblasts, which may then deposit mucin in the dermis. The identity of the fibroblast stimulatory agent remains unknown. Previous reports10 attributed this to paraproteins; however, the stimulation of fibroblasts occurs even after the removal of the paraprotein. Further evidence against paraproteins as a causative agent in patients with scleromyxedema is that paraprotein levels do not correlate with disease severity or progression.11 These findings were not confirmed by another group. They demonstrated that the serum could induce a 2-fold increase in hyaluronic acid synthesis and a 13-fold increase in prostaglandin E synthesis. Thus, the role of the monoclonal protein in the pathogenesis of scleromyxedema is uncertain.10-12

Scleromyxedema remains a therapeutic challenge. Reported treatments include dermabrasion,13 psoralen–UV-A,14 systemic retinoids,15,16 and corticosteroids.7,17,18 Other reports of successful treatment include granulocyte colony-stimulating factor,19 plasmapheresis,20 external beam irradiation,21 intravenous immunoglobulin,22 interferon alfa-2a,23 and extracorporal photopheresis.24 Multiple chemotherapeutic agents have been used, including melphalan,5,25,26 cyclosporine,27 cladribine,28 cyclophosphamide,29,30 methotrexate,31,32 and chlorambucil.33 Despite all these reported trials, most patients with scleromyxedema do not show a significant response to therapy. The use of these chemotherapeutic agents is limited by toxicity and numerous adverse effects.

It is thought that in patients with scleromyxedema and plasma cell dyscrasia there might be a link with multiple myeloma. This theory is the basis behind the use of alkylating agents. Therefore, the purpose of using chemotherapeutic agents is to disrupt the plasma cell dyscrasia and monoclonal gammopathy. Although the relationship between these disorders is uncertain, scleromyxedema responds to antimetabolites, especially melphalan. In some cases, treatment with melphalan has resulted in the disappearance of the monoclonal protein, with improvement of the skin condition.26 However, other studies25,26 have shown clinical improvement with a variable effect on the immunoglobulin levels. Unfortunately, the use of these medications increases the risk of secondary malignancies, hematologic abnormalities, and sepsis.5,6

We chose thalidomide after its reported success in treating multiple myeloma.34-36 We theorized that, like melphalan, which is also used in patients with multiple myeloma, thalidomide might also be effective in patients with scleromyxedema. Thalidomide has been used to treat patients with refractory and relapsed multiple myeloma. Thalidomide also disrupts the plasma cell dyscrasia.

Thalidomide is US Food and Drug Administration approved for the treatment of erythema nodosum leprosum, but given its history of teratogenicity, its use is tightly regulated. In the United States, it is only available through physicians registered with Celgene Corporation (Warren, NJ) and the STEPS program. The STEPS program is designed to prevent pregnancy in patients receiving thalidomide and requires intensive contraceptive counseling, monthly pregnancy tests, and telephone surveys. Thalidomide can also cause drowsiness, dizziness, constipation, amenorrhea, and potentially irreversible sensory neuropathy. It is recommended that patients receiving thalidomide undergo baseline and biannual nerve studies to monitor for the development of neuropathy.

The mechanism of action of thalidomide is unknown. It has immunomodulatory, anti-inflammatory, neural, and vascular effects. Thalidomide exhibits specific inhibition of tumor necrosis factor α.37 Humoral immunity is affected, as shown by the suppression of interleukin 1238 and the simultaneous enhancement of interleukins 4 and 5 with interferon γ inhibition.39 It has also been shown to decrease neutrophil chemotaxis and phagocytosis40,41 and monocyte phagocytosis.42 Thalidomide has also been shown to inhibit angiogenesis by an unknown mechanism.43 The study by Verheul and colleagues44 also showed inhibition of carcinoma growth in rabbits. This property may allow its use as an antineoplastic agent. It is possible that thalidomide might inhibit the circulating factor that stimulates fibroblast production, thus reversing the progression of scleromyxedema.

We believe that the use of thalidomide was justified in our patient because of a possibly related seizure disorder, progressive disability, and lack of response to other accepted therapies. Her response to thalidomide was dramatic. Thalidomide might represent an effective treatment option in patients with scleromyxedema, and further study is warranted.


Corresponding author: Heidi Jacobe, MD, Department of Dermatology, The University of Texas–Southwestern, 5323 Harry Hines Blvd, Dallas, TX 75390 (e-mail:

Accepted for publication June 25, 2003.

The authors have no relevant financial interest in this article.


Clinicians, local and regional societies, residents, and fellows are invited to submit cases of challenges in management and therapeutics to this section. Cases should follow the established pattern. Submit 4 double-spaced copies of the manuscript with right margins nonjustified and 4 sets of the illustrations. Photomicrographs and illustrations must be clear and submitted as positive color transparencies (35-mm slides) or black-and-white prints. Do not submit color prints unless accompanied by original transparencies. Material should be accompanied by the required copyright transfer statement, as noted in "Instructions for Authors." Material for this section should be submitted to George J. Hruza, MD, Laser and Dermatologic Surgery Center Inc, 14377 Woodlake Dr, Suite 111, St Louis, MO 63017.

Dubreuilh  W Fibromes miliaires folliculaires: sclerodemie consecutive  Ann Dermatol Syph. 1906;37569- 572Google Scholar
Reitmann  K Uber eine eigenartige, der sklerodermie nahestehende affektion  Arch Dermatol Syph. 1908;92417- 424Google ScholarCrossref
Montgomery  HUnderwood  LJ Lichen myxedematosus (differentiation from cutaneous myxedemas or mucoid states)  J Invest Dermatol. 1953;20213- 236Google Scholar
Gottron  HA Skleromyxodem (eine eigenartige erscheinung Form von Myxothesaurodermie)  Arch Dermatol Syph (Berl). 1954;19971- 91Google ScholarCrossref
Gabriel  SEPerry  HOOleson  GBBowles  CA Scleromyxedema: a scleroderma-like disorder with systemic manifestations  Medicine (Baltimore). 1988;6758- 65PubMedGoogle ScholarCrossref
Dinnen  AMDicken  CH Scleromyxedema  J Am Acad Dermatol. 1995;3337- 43PubMedGoogle ScholarCrossref
McCuiston  CHSchoch Jr  EP Autopsy findings in lichen myxedematosus  Arch Dermatol. 1956;74259- 262Google ScholarCrossref
Kantor  GRBergfeld  WFKatzin  WE Scleromyxedema associated with scleroderma renal disease and acute psoriasis  J Am Acad Dermatol. 1986;14879- 888PubMedGoogle ScholarCrossref
Godby  ABergstresser  PRChaker  BPandya  AG Fatal scleromyxedema: report of a case and review of the literature  J Am Acad Dermatol. 1998;38289- 294PubMedGoogle ScholarCrossref
Harper  RARispler  J Lichen myxedematosus serum stimulates human skin fibroblast proliferation  Science. 1978;199545- 547PubMedGoogle ScholarCrossref
Chandra  JJ Scleromyxedema  Cutis. 1979;24549- 552PubMedGoogle Scholar
Ferrarini  MHelfrich  DJWalker  ERMedsger Jr  TAWhiteside  TL Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts  J Rheumatol. 1989;16837- 841PubMedGoogle Scholar
Kaufman  DTruha  APRoenigk Jr  HH Scleromyxedema: systemic manifestations and cosmetic improvement with dermabrasion  Cutis. 1987;39321- 324PubMedGoogle Scholar
Farr  PMIve  FA PUVA treatment of scleromyxoedema  Br J Dermatol. 1984;110347- 350PubMedGoogle ScholarCrossref
Milam  CPCohen  LEFenske  NALing  NS Scleromyxedema: therapeutic response to isotretinoin in three patients  J Am Acad Dermatol. 1988;19469- 477PubMedGoogle ScholarCrossref
Hisler  BMSavoy  LBHashimoto  K Improvement of scleromyxedema associated with isotretinoin therapy  J Am Acad Dermatol. 1991;24854- 857PubMedGoogle ScholarCrossref
Rudner  EJMehregan  APinkus  H Scleromyxedema: a variant of Lichen myxedematosus  Arch Dermatol. 1966;933- 12PubMedGoogle ScholarCrossref
Perry  HOMontgomery  HStickney  JM Further observations on lichen myxedematosus  Ann Intern Med. 1960;53955- 969Google ScholarCrossref
Cohen  AMHodar  EDavid  MMittelman  MGal  RStern  R Beneficial effect of granulocyte-colony stimulating factor in scleromyxedema associated with severe idiopathic neutropenia  Br J Dermatol. 1996;135626- 629PubMedGoogle ScholarCrossref
MacFarlane  AWDavenport  AVerbov  JLGoldsmith  HJ Scleromyxoedema: successful treatment with plasma exchange and immunosuppression  Br J Dermatol. 1987;117653- 657PubMedGoogle ScholarCrossref
Lowe  NJDufton  PAHunter  RDVickers  CF Electron-beam treatment of scleromyxoedema  Br J Dermatol. 1982;106449- 453PubMedGoogle ScholarCrossref
Lister  RKJolles  SWhittaker  S  et al.  Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg)  J Am Acad Dermatol. 2000;43403- 408PubMedGoogle ScholarCrossref
Tschen  JAChang  JR Scleromyxedema: treatment with interferon alfa  J Am Acad Dermatol. 1999;40303- 307PubMedGoogle ScholarCrossref
Berkson  MLazarus  GSUberti-Benz  MRook  AH Extracorporeal photochemotherapy: a potentially useful treatment for scleromyxedema  J Am Acad Dermatol. 1991;25724PubMedGoogle ScholarCrossref
Feldman  PShapiro  LPick  AISlatkin  MH Scleromyxedema: a dramatic response to melphalan  Arch Dermatol. 1969;9951- 56PubMedGoogle ScholarCrossref
Harris  RBPerry  HOKyle  RAWinkelmann  RK Treatment of scleromyxedema with melphalan  Arch Dermatol. 1979;115295- 299PubMedGoogle ScholarCrossref
Bata-Csorgo  ZHusz  SFoldes  M  et al.  Scleromyxedema  J Am Acad Dermatol. 1999;41343- 346PubMedGoogle ScholarCrossref
Davis  LSSanal  SSangueza  OP Treatment of scleromyxedema with 2-chlorodeoxyadenosine  J Am Acad Dermatol. 1996;35288- 290PubMedGoogle ScholarCrossref
Howsden  SMHerndon Jr  JHFreeman  RG Lich myxedematosus: a dermal infiltrative disorder responsive to cyclophosphamide therapy  Arch Dermatol. 1975;1111325- 1330PubMedGoogle ScholarCrossref
Jessen  RTStraight  MBecker  LE Lichen myxedematosus: treatment with cyclophosphamide  Int J Dermatol. 1978;17833- 839PubMedGoogle ScholarCrossref
Verity  MAToop  JMcAdam  LPPearson  CM Scleromyxedema myopathy: histochemical and electron microscopic observations  Am J Clin Pathol. 1978;69446- 451PubMedGoogle Scholar
McAdam  LPPearson  CMPitts  WHSadoff  LVerity  MA Papular mucinosis with myopathy, arthritis, and eosinophilia: a histopathologic study  Arthritis Rheum. 1977;20989- 996PubMedGoogle ScholarCrossref
Wieder  JMBarton  KLBaron  JMSoltani  K Lichen myxedematosus treated with chlorambucil  J Dermatol Surg Oncol. 1993;19475- 476PubMedGoogle ScholarCrossref
Kneller  ARaanani  PHardan  I  et al.  Therapy with thalidomide in refractory multiple myeloma patients: the revival of an old drug  Br J Haematol. 2000;108391- 393PubMedGoogle ScholarCrossref
Juliusson  GCelsing  FTuresson  ILenhoff  SAdriansson  MMalm  C Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma  Br J Haematol. 2000;10989- 96PubMedGoogle ScholarCrossref
Rajkumar  SVFonseca  RDispenzieri  A  et al.  Thalidomide in the treatment of relapsed multiple myeloma  Mayo Clin Proc. 2000;75897- 901PubMedGoogle ScholarCrossref
Sampaio  EPSarno  ENGalilly  RCohn  ZAKaplan  G Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes  J Exp Med. 1991;173699- 703PubMedGoogle ScholarCrossref
Moller  DRWysocka  MGreenlee  BM  et al.  Inhibition of IL-12 production by thalidomide  J Immunol. 1997;1595157- 5161PubMedGoogle Scholar
McHugh  SMRifkin  IRDeighton  J  et al.  The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures  Clin Exp Immunol. 1995;99160- 167PubMedGoogle ScholarCrossref
Hastings  RC Kellersberger Memorial Lecture 1979: immunosuppressive/anti-inflammatory thalidomide analogues  Ethiop Med J. 1980;1865- 71PubMedGoogle Scholar
Faure  MThivolet  JGaucherand  M Inhibition of PMN leukocytes chemotaxis by thalidomide  Arch Dermatol Res. 1980;269275- 280PubMedGoogle ScholarCrossref
Barnhill  RLDoll  NJMillikan  LEHastings  RC Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes  J Am Acad Dermatol. 1984;11814- 819PubMedGoogle ScholarCrossref
D'Amato  RJLoughnan  MSFlynn  EFolkman  J Thalidomide is an inhibitor of angiogenesis  Proc Natl Acad Sci U S A. 1994;914082- 4085PubMedGoogle ScholarCrossref
Verheul  HMPanigrahy  DYuan  JD'Amato  RJ Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits  Br J Cancer. 1999;79114- 118PubMedGoogle ScholarCrossref